Investor Presentaiton
For personal use only
STARLITE 2 Phase II trial of TLX250 for treatment of CCRCC
TLX250 in combination with immunotherapy
•
•
•
STARLITE 2 now actively recruiting (screening patients)
Phase II trial of TLX250 plus nivolumab with ccRCC who have progressed
following prior immunotherapy
Evaluates TLX250-delivered radiation as an immune system "primer"
-
Targets carbonic anhydrase IX (CA9) – a protein highly expressed in
patients that are likely to demonstrate a more limited response to cancer
immunotherapy
Primary endpoint
To determine the safety and efficacy of combination therapy with 177Lu-
girentuximab (TLX250) FDA Investigational New Drug Application (IND)
accepted for STARLITE 2 study, being undertaken at Memorial Sloan
Kettering Cancer Centre
Additional Phase II study - STARLITE 1 - (first-line combination study) to be
initiated at a second US site (awaiting ethics approval)
% Overall survival
100
80
60
40
20
20
0
0
20
40 60 80
Months
100
L
100
% Overall survival
80
60
40-
20-
0
T
T
0
20 40 60 80
Months
100
TELIX
PHARMACEUTICALS
CA9NL 54 pts
-CA9WH 44 pts
p = 0.15
TIL-score12
-TIL-score 34 42 pts
56 pts
p = 0.05
1. Giatromanolaki et al. British Journal of Cancer. 2020.
Telix Pharmaceuticals Limited (ASX: TLX)
CA9 expression is correlated with
the presence of tumour-infiltrating
lymphocytes, which may confer
resistance to immunotherapy.1
43View entire presentation